NeoSight Neoantigen Detection
Immuno-oncology
Research/ClinicalActive
Key Facts
About ReproCELL
ReproCELL is a UK-based, privately-held life sciences company founded in 2003, operating at the intersection of stem cell technology, drug discovery, and precision medicine. It has evolved from a stem cell product supplier into an integrated global provider of research tools, GMP-compliant cell manufacturing, and human tissue-based preclinical contract research services. The company leverages strategic acquisitions to build a diversified portfolio that supports the entire drug development pipeline, from discovery through to clinical-stage cell therapy manufacturing. Its focus on human-derived models and regulatory-compliant services positions it as a key enabler for translational research.
View full company profileTherapeutic Areas
Other Immuno-oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| PD-1/PD-L1 Inhibitor Binding Assay Kit | Aurora Biolabs | Commercial |
| CTLA-4/B7-1 Inhibitor Screening Kit | Aurora Biolabs | Commercial |
| OX40 & PD-1 Assay | Aurora Biolabs | Commercial |
| HPK1 inhibitor | Acellera | Pre-clinical |
| SKP2-CKS1 PPI Inhibitor | Iktos | Hit-to-Lead |
| PD-1 Expression Inhibitor | BCN Biosciences | Preclinical |
| CCR8 ADC | Integral Molecular | Preclinical |
| KB16A | KBio | Discovery |
| EMUNKITUG (HFB200301) | HiFiBiO Therapeutics | Phase 1 |
| HFB200603 | HiFiBiO Therapeutics | Phase 1 |
| Undisclosed Multispecific Therapeutics | ModeX Therapeutics | Pre-clinical |
| Undisclosed | Onco3R Therapeutics | Preclinical |